Calithera Biosciences, Inc.

CALA

US13089P5070

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 14:07:21 2024-05-28 EDT			5-day change	1st Jan Change
0.02 ^USD	0.00%		0.00%	-33.33%

2023	Calithera Biosciences, Inc. Launches the Cala kIQ System, Offering Meaningful Tremor Relief for Patients with Essential Tremor and Now Parkinson’s Disease	CI
2023	North American Morning Briefing : Stock Futures -2-	DJ

Calithera Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021

March 31, 2022 at 04:42 pm

Calithera Biosciences, Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported revenue was USD 9.75 million. Net loss was USD 115.09 million compared to USD 90.14 million a year ago.

Basic loss per share from continuing operations was USD 31.2 compared to USD 26.2 a year ago.

Latest news about Calithera Biosciences, Inc.

Calithera Biosciences, Inc. Launches the Cala kIQ System, Offering Meaningful Tremor Relief for Patients with Essential Tremor and Now Parkinson’s Disease	23-06-14	CI
North American Morning Briefing : Stock Futures -2-	23-05-23	DJ
North American Morning Briefing : Retail Sales, -2-	23-05-16	DJ
Calithera Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Calithera Biosciences, Inc. Auditor Raises 'Going Concern' Doubt	23-03-30	CI
Calithera Biosciences, Inc.(NasdaqGS:CALA) dropped from S&P TMI Index	23-02-06	CI
Calithera Biosciences, Inc.(NasdaqGS:CALA) dropped from NASDAQ Composite Index	23-02-01	CI
Top Premarket Decliners	23-01-25	MT
Calithera Biosciences Shares Set to be Suspended From Nasdaq on Feb. 2; Stock Declines Premarket	23-01-25	MT
Top Midday Decliners	23-01-09	MT
Calithera Biosciences to Proceed With Liquidation and Dissolution of Company	23-01-09	MT
Calithera Biosciences, Inc. Announces Departure of Susan M. Molineaux as Chief Executive Officer	23-01-09	CI
Calithera Biosciences, Inc. Announces Departure of Stephanie Wong as Chief Financial Officer	23-01-09	CI
Calithera Biosciences, Inc. Announces Executive Departures	23-01-09	CI
Antengene Signs Assignment Deal with Calithera to Acquire Rights on Cancer Tumor Drug; Shares Climb 10%	23-01-04	MT
Antengene Corporation Limited Enters into Assignment Agreement with Calithera Biosciences, Inc. to Acquire All Outstanding Rights of ATG-037	23-01-04	CI
North American Morning Briefing : Stock Futures -2-	22-11-16	DJ
Ladenburg Thalmann Downgrades Calithera Biosciences to Neutral From Buy	22-11-15	MT
SVB Securities Downgrades Calithera Biosciences to Market Perform From Outperform, Adjusts Price Target to $2 From $18	22-11-15	MT
Calithera Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Transcript : Calithera Biosciences, Inc., Q3 2022 Earnings Call, Nov 14, 2022	22-11-14
Calithera Biosciences, Inc. cancelled the transaction announced on October 18, 2021	22-10-17	CI
Health Care Up Amid Deal Activity -- Health Care Roundup	22-10-03	DJ
Calithera Biosciences Receives FDA's Fast Track Designation for Lung Cancer Drug Candidate; Shares Climb	22-10-03	MT
Calithera Biosciences, Inc. Receives U.S. Food & Drug Administration Fast Track Designation for Sapanisertib for the Treatment of NRF2-Mutated Squamous Lung Cancer	22-10-03	CI

Chart Calithera Biosciences, Inc.

Duration

Period

More charts

Company Profile

Calithera Biosciences, Inc. is a shell company. The Company is winding up its operations. The Company is seeking to sell all of its clinical assets and programs. The Company has not generated any revenue.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CALITHERA BIOSCIENCES, INC.	-33.33%	97.45K
ELI LILLY AND COMPANY	+38.59%	727B
JOHNSON & JOHNSON	-7.89%	347B
MERCK & CO., INC.	+15.66%	319B
ABBVIE INC.	+0.24%	274B
ASTRAZENECA PLC	+13.00%	238B
NOVARTIS AG	+6.95%	204B
ROCHE HOLDING AG	-6.46%	203B
AMGEN INC.	+4.23%	161B
PFIZER, INC.	-1.70%	160B

Other Pharmaceuticals